Arvinas Inc. (Nasdaq: ARVN) received landmark U.S. Food and Drug Administration approval for its cancer drug Vepdegestrant, the first-ever approved therapy based on PROTAC protein degradation, which extended progression-free survival by 138 percent in a pivotal trial.
“The approval of VEPPANU is a defining achievement for Arvinas and reflects the culmination of more than a decade of focused work to translate our PROTAC science into our first approved therapy,” Randy Teel, Ph.D., President and Chief Executive Officer at Arvinas, said in a statement.
The approval for Vepdegestrant, brand name VEPPANU, is for adults with ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations that has progressed after at least one line of endocrine therapy. In the VERITAC-2 trial, patients with these mutations saw a median progression-free survival of 5.0 months on Vepdegestrant, compared to 2.1 months for those on the standard-of-care treatment fulvestrant. The objective response rate was 19 percent for the Vepdegestrant group, nearly five times the 4 percent seen in the fulvestrant arm.
The approval validates Arvinas’s entire PROTAC platform, which harnesses the body’s own cellular machinery to destroy disease-causing proteins. Concurrent with the news, Arvinas and its partner Pfizer Inc. (NYSE: PFE) announced an exclusive global licensing deal for Vepdegestrant with Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL). The deal provides an $85 million upfront payment and up to $320 million in future milestones, plus tiered royalties.
Under the terms of the agreement, Rigel will take over global development and commercialization. Arvinas and Pfizer will receive an initial $70 million and an additional $15 million upon completion of transition activities. Rigel will also contribute up to $40 million toward current ongoing development activities. This transaction allows Arvinas to bolster its balance sheet, with the company reporting cash and marketable securities of $614.9 million as of March 31, 2026, which it believes is sufficient to fund operations into the second half of 2028.
The FDA’s decision supports the potential of Arvinas’s broader pipeline of protein degraders. Key programs include ARV-102 for Parkinson’s disease, ARV-806 targeting KRAS-mutated cancers, and several other candidates in early-stage development for oncology and rare diseases.
The approval of Vepdegestrant serves as a major de-risking event for Arvinas's technology platform. Investors will now focus on the successful commercial launch by Rigel and upcoming data from Arvinas's pipeline assets throughout 2026.
This article is for informational purposes only and does not constitute investment advice.
